Stephen Hugh Caldwell
#129,640
Most Influential Person Now
Stephen Hugh Caldwell's AcademicInfluence.com Rankings
Stephen Hugh Caldwellphilosophy Degrees
Philosophy
#6251
World Rank
#9253
Historical Rank
Logic
#3433
World Rank
#4588
Historical Rank
Stephen Hugh Caldwellbiology Degrees
Biology
#8453
World Rank
#11530
Historical Rank
Biochemistry
#1229
World Rank
#1348
Historical Rank
Download Badge
Philosophy Biology
Stephen Hugh Caldwell's Degrees
- Doctorate Medicine University of California, San Francisco
- PhD Biochemistry University of California, San Francisco
Why Is Stephen Hugh Caldwell Influential?
(Suggest an Edit or Addition)Stephen Hugh Caldwell's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference (2003) (2172)
- Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease (1999) (1111)
- Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. (2012) (742)
- Liver biopsy (2009) (580)
- Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. (2009) (501)
- The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. (2004) (495)
- Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management (2006) (466)
- Mitochondrial abnormalities in non-alcoholic steatohepatitis. (1999) (446)
- The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial (2017) (405)
- Obesity and hepatocellular carcinoma. (2004) (396)
- Coagulopathy Does Not Fully Protect Hospitalized Cirrhosis Patients from Peripheral Venous Thromboembolism (2006) (364)
- Epidemiology and natural history of non-alcoholic steatohepatitis. (2009) (360)
- Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. (2015) (358)
- Hemostasis and thrombosis in patients with liver disease: the ups and downs. (2010) (324)
- Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. (2000) (296)
- Intensive care of patients with acute liver failure: Recommendations of the U.S. Acute Liver Failure Study Group (2007) (291)
- A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis (2001) (285)
- Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. (1996) (282)
- Evidence‐based practice guidelines for plasma transfusion (2010) (265)
- The Natural History of Non-Alcoholic Fatty Liver Disease (2010) (254)
- Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (2018) (254)
- Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis (2017) (248)
- AGA Clinical Practice Update: Coagulation in Cirrhosis. (2019) (233)
- Coagulation in liver disease: a guide for the clinician. (2013) (232)
- Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. (2016) (231)
- Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy (2003) (221)
- The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology (2009) (215)
- Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials. (2020) (214)
- Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. (2018) (208)
- Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation (2016) (201)
- Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C (2003) (197)
- Hepatocellular ballooning in NASH. (2010) (189)
- Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. (2015) (179)
- Systematic review with meta‐analysis: risk of hepatocellular carcinoma in non‐alcoholic steatohepatitis without cirrhosis compared to other liver diseases (2018) (174)
- Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. (2019) (165)
- A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. (2001) (155)
- The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials (2019) (150)
- Changing Concepts of Cirrhotic Coagulopathy (2017) (148)
- Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation (1996) (142)
- The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis (2019) (140)
- Is NASH underdiagnosed among African Americans? (2002) (140)
- Endoscopic cyanoacrylate versus transjugular intrahepatic portosystemic shunt for gastric variceal bleeding: a single-center U.S. analysis. (2009) (132)
- Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. (2019) (132)
- Treatment of congestive heart failure. Its effect on pleural fluid chemistry. (1989) (131)
- Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. (1998) (130)
- Statins in liver disease: A molehill, an iceberg, or neither? (2008) (122)
- Mitochondria in nonalcoholic fatty liver disease. (2004) (118)
- Ectopic varices: anatomical classification, hemodynamic classification, and hemodynamic-based management. (2013) (112)
- Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis (2015) (110)
- NASH and cryptogenic cirrhosis: a histological analysis. (2009) (109)
- Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH (2020) (107)
- The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis (2004) (103)
- A prospective study of conventional and expanded coagulation indices in predicting ulcer bleeding after variceal band ligation. (2009) (102)
- Combination of N‐acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non‐alcoholic steatohepatitis (2007) (98)
- Bleeding gastric varices obliteration with balloon-occluded retrograde transvenous obliteration using sodium tetradecyl sulfate foam. (2011) (97)
- N-2-butyl-cyanoacrylate for bleeding gastric varices: a United States pilot study and cost analysis (2003) (97)
- Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding (2014) (94)
- A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma. (2008) (88)
- Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease (2019) (88)
- Expression of perilipin and adipophilin in nonalcoholic fatty liver disease; relevance to oxidative injury and hepatocyte ballooning. (2009) (86)
- Genetic inhibition of hepatic acetyl-CoA carboxylase activity increases liver fat and alters global protein acetylationa (2014) (86)
- Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case‐control study (2018) (84)
- ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation. (2020) (84)
- Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry (2016) (80)
- Performance of the Hepatic Encephalopathy Scoring Algorithm in a Clinical Trial of Patients With Cirrhosis and Severe Hepatic Encephalopathy (2009) (77)
- Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues (2010) (75)
- Therapy of NAFLD: Antioxidants and Cytoprotective Agents (2006) (75)
- AASLD position paper: Liver biopsy (2008) (70)
- Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients (2009) (70)
- Variation between centers in technique and guidelines for liver biopsy. (2008) (68)
- Controversies in the Diagnosis and Management of NAFLD and NASH. (2014) (68)
- Procoagulant therapeutics in liver disease: a critique and clinical rationale (2014) (67)
- Short-term rebleeding rates for isolated gastric varices managed by transjugular intrahepatic portosystemic shunt versus balloon-occluded retrograde transvenous obliteration. (2014) (67)
- Subacute liver failure in obese women (2002) (66)
- Practice patterns in NAFLD and NASH: real life differs from published guidelines (2016) (66)
- Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: A break from convention in need of controlled trials (2004) (64)
- Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series (2015) (63)
- A clinical survey of bleeding, thrombosis, and blood product use in decompensated cirrhosis patients. (2012) (62)
- Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis (2009) (62)
- Hepatic Decompensation Likely Attributable to Simeprevir in Patients with Advanced Cirrhosis (2015) (62)
- Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? (2009) (62)
- Hepatitis C infection by polymerase chain reaction in alcoholics: false-positive ELISA results and the influence of infection on a clinical prognostic score. (1993) (59)
- Treating thrombosis in cirrhosis patients with new oral agents: Ready or not? (2015) (59)
- Inhibition of hepatic lipogenesis enhances liver tumorigenesis by increasing antioxidant defence and promoting cell survival (2017) (59)
- Medical and endoscopic management of gastric varices. (2011) (57)
- Antibody to hepatitis C is common among patients with alcoholic liver disease with and without risk factors. (1991) (55)
- Protective Value of TIPS Against the Development of Hydrothorax/Ascites and Upper Gastrointestinal Bleeding after Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) (2013) (53)
- Corrections: Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference (2003) (51)
- Dietary effects on liver tumor burden in mice treated with the hepatocellular carcinogen diethylnitrosamine. (2015) (51)
- Therapy of NAFLD: insulin sensitizing agents. (2006) (51)
- Gastric and ectopic varices. (2014) (50)
- Is NASH underdiagnosed among African Americans (2002) (49)
- Ancient remedies revisited: does Allium sativum (garlic) palliate the hepatopulmonary syndrome? (1992) (48)
- The role of recombinant factor VIIa in liver transplantation (2005) (48)
- Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant (2011) (46)
- Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis (2018) (46)
- Bilirubin alone as a biomarker for short-term mortality in acute-on-chronic liver failure: an important prognostic indicator. (2013) (46)
- Liver transplantation: incidence and management of deep venous thrombosis and pulmonary emboli. (1997) (44)
- Bleeding and thrombosis in cirrhotic patients: what really matters? (2012) (43)
- The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. (2018) (42)
- Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis (2017) (42)
- Hypercoagulation and Thrombophilia in Nonalcoholic Fatty Liver Disease: Mechanisms, Human Evidence, Therapeutic Implications, and Preventive Implications (2012) (41)
- Direct Oral Anticoagulants in Cirrhosis (2016) (40)
- Troglitazone-associated hepatic failure (2000) (39)
- Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)? (2007) (39)
- Correction of hemostatic abnormalities and portal pressure variations in patients with cirrhosis (2014) (39)
- Is exercise an effective treatment for NASH? Knowns and unknowns. (2009) (39)
- Gastric Varices: Is There a Role for Endoscopic Cyanoacrylates, or Are We Entering the BRTO Era? (2012) (37)
- NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs (2017) (37)
- Predictive value of intraoperative biopsies and liver function tests for preservation injury in orthotopic liver transplantation. (1997) (37)
- Advanced non-alcoholic steatohepatitis cirrhosis: A high-risk population for pre-liver transplant portal vein thrombosis (2017) (37)
- Hepatitis C virus in body fluids after liver transplantation. (1996) (36)
- Retransplantation of patients with severe posttransplant hepatitis B in the first allograft. (1997) (36)
- Regional citrate anticoagulation in critically ill patients with liver and kidney failure. (2012) (36)
- A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. (2021) (36)
- DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. (2018) (34)
- Subacute liver failure in obese women. (2002) (34)
- Cryptogenic Cirrhosis: What Are We Missing? (2010) (34)
- Quality of life of hepatitis B and C patients after liver transplantation. (1997) (33)
- Reversal of direct oral anticoagulants for liver transplantation in cirrhosis: A step forward (2017) (33)
- Antimitochondrial antibodies in kindreds of patients with primary biliary cirrhosis: Antimitochondrial antibodies are unique to clinical disease and are absent in asymptomatic family members (1992) (32)
- Bleeding Risk and Management in Interventional Procedures in Chronic Liver Disease. (2017) (32)
- The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis (2007) (29)
- Thiazolidinediones for the Treatment in NASH: Sustained Benefit After Drug Discontinuation? (2009) (28)
- Acute hepatitis with use of over-the-counter herbal remedies. (1994) (28)
- Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C. (2017) (28)
- Pre- and post-balloon-occluded retrograde transvenous obliteration clinical evaluation, management, and imaging: indications, management protocols, and follow-up. (2012) (27)
- Peripheral platelet count correlates with liver atrophy and predicts long‐term mortality on the liver transplant waiting list (2013) (27)
- Dietary sugar intake increases liver tumor incidence in female mice (2016) (26)
- Use of fibrin sealant to reduce bleeding after needle liver biopsy in an anticoagulated canine model: work in progress. (1999) (26)
- Accuracy and significance of pretransplant liver volume measured by magnetic resonance imaging (1996) (26)
- Prediction of bleeding in cirrhosis patients: Is the forecast any clearer? (2016) (26)
- Lipid droplet-associated proteins in alcoholic liver disease: a potential linkage with hepatocellular damage. (2015) (25)
- The international autoimmune hepatitis score in chronic hepatitis C (1997) (25)
- CASE REPORT: Myositis, Microvesicular Hepatitis, and Progression to Cirrhosis from Troglitazone Added to Simvastatin (2001) (25)
- Enlarged Hepatocytes in NAFLD Examined with Osmium Fixation: Does Microsteatosis Underlie Cellular Ballooning in NASH? (2006) (24)
- Coagulation Pathways, Hemostasis, and Thrombosis in Liver Failure (2018) (24)
- Bleeding complication with liver biopsy: is it predictable? (2010) (24)
- JKB-121 in patients with nonalcoholic steatohepatitis: A phase 2 double blind randomized placebo control study (2018) (24)
- Controlling pain in liver biopsy, or “we will probably need to repeat the biopsy in a year or two to assess the response” (2001) (24)
- Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment (2010) (23)
- Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. (2020) (23)
- Incidence and Recurrence of Portal Vein Thrombosis in Cirrhotic Patients (2019) (23)
- Non-alcoholic Fatty Liver Disease: Not Time for an Obituary Just Yet! (2020) (23)
- The Effect of Balloon-Occluded Transvenous Obliteration of Gastric Varices and Gastrorenal Shunts on the Hepatic Synthetic Function (2013) (22)
- Hemostasis in chronic liver disease (2006) (22)
- Efficacy and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebo-controlled trials (2017) (22)
- Balloon-occluded Retrograde Transvenous Obliteration (BRTO): Preprocedural Evaluation and Imaging. (2011) (21)
- Cryptogenic vs. NASH-cirrhosis: The rose exists well before its name.... (2017) (20)
- Non‐Alcoholic Fatty Liver Disease and Nutrition (2011) (20)
- Viscoelastic Testing in Liver Disease. (2018) (20)
- Intermittent disconjugate gaze: A novel finding in nonalcoholic steatohepatitis and cryptogenic cirrhosis (2005) (20)
- Yo Jyo Hen Shi Ko, a novel Chinese herbal, prevents nonalcoholic steatohepatitis in ob/ob mice fed a high fat or methionine–choline‐deficient diet (2007) (19)
- Viscoelastic Testing in Liver Disease. (2018) (19)
- Balloon Retrograde Transvenous Obliteration Versus Endoscopic Cyanoacrylate in Bleeding Gastric Varices: Comparison of Rebleeding and Mortality with Extended Follow-up. (2019) (19)
- Duodenal bulb biopsy findings for patients with non-ulcer dyspepsia with or without Campylobacter pylori gastritis. (1990) (19)
- Management of coagulopathy in liver disease. (2014) (18)
- Nonalcoholic steatohepatitis: a twenty-first century epidemic? (2006) (18)
- New concepts of coagulation and bleeding in liver disease (2010) (18)
- Combined transmesenteric and transhepatic recanalization of chronic portal and mesenteric vein occlusion to treat bleeding duodenal varices. (2014) (18)
- Helicobacter pylori infection and gastric emptying of solids in humans (1992) (17)
- Methodological issues with coagulation testing in patients with liver disease. (2006) (17)
- Is chronic liver disease associated with a bleeding diathesis? (2006) (17)
- Prevention of hepatitis B "rerecurrence" after a second liver transplant--the role of maintenance polyclonal HBIG therapy. (1994) (16)
- Coagulation disorders and bleeding in liver disease: future directions. (2009) (16)
- The cirrhotic platelet: Shedding light on an enigma (2017) (16)
- Subumbilical midline vascularity of the abdominal wall in portal hypertension observed at laparoscopy. (1998) (16)
- Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (2021) (15)
- Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial. (2018) (15)
- Clinical course of four patients receiving the experimental antiviral agent fialuridine for the treatment of chronic hepatitis B infection. (1995) (15)
- Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C. (2017) (14)
- Consequences of abnormal hemostasis tests for clinical practice. (2006) (14)
- Carbohydrate‐deficient transferrin in alcoholics with liver disease (1995) (14)
- Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists (2019) (14)
- A Randomized Controlled Trial of Procedural Techniques for Large Volume Paracentesis. (2017) (13)
- Management of bleeding ectopic varices (2017) (13)
- Treatment of Primary Liver Tumors with Yttrium-90 Microspheres (TheraSphere®) in High Risk Patients: Analysis of Survival and Toxicities (2009) (13)
- The liver and statin drug therapy: uncertain navigation in the sea of risk‐benefit (2003) (13)
- Serial MRI Imaging Reveals Minimal Impact of Ketogenic Diet on Established Liver Tumor Growth (2018) (13)
- Modulation of hepatic microsomal triglyceride transfer protein (MTP) induced by S-nitroso-N-acetylcysteine in ob/ob mice. (2007) (13)
- Clinical Characterization of Gastric Antral Vascular Ectasia: A Potential Manifestation of the Metabolic Syndrome. (2016) (13)
- Perspectives on NASH Histology: Cellular Ballooning. (2017) (13)
- Accuracy and significance of pretransplant liver volume measured by magnetic resonance imaging. (1997) (12)
- Perspectives on cellular dysfunction in nonalcoholic steatohepatitis: a case of ‘multiorganelle failure’? Proceedings of a virtual workshop on nonalcoholic steatohepatitis (2011) (12)
- The prothrombin time‐derived international normalized ratio: great for Warfarin, fair for prognosis and bad for liver‐bleeding risk (2008) (11)
- LBO-02-Elafibranor, a peroxisome proliferator-activted receptor alpha and delta agonist demonstrates favourable efficacy and safety in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid treatment (2019) (11)
- Portal vein thrombosis in cirrhosis: ignore, prevent, or treat? (2013) (11)
- Divergent effects of peroxisome proliferator–activated receptor‐γ ligands in human and mouse nonalcoholic steatohepatitis (2007) (11)
- Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis (2017) (11)
- Dismantling the myth of “autoanticoagulation” in cirrhosis: An old dogma dies hard (2012) (10)
- Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease : Proceedings of the 7 th International Coagulation in Liver Disease Conference October 6 th and 7 th , 2017 Rome , Italy (2018) (10)
- Nails in the coffin of fresh frozen plasma to prevent or treat bleeding in cirrhosis? (2019) (10)
- The role of anti-fibrinolytics, rFVIIa and other pro-coagulants: prophylactic versus rescue? (2009) (10)
- Anemia as a potential contributor to bleeding in patients with liver disease - Neglected but not forgotten (2011) (10)
- Thrombosis of the Portal Venous System in Cirrhotic vs. Non-Cirrhotic Patients. (2018) (10)
- Acute kidney injury is associated with low factor XIII in decompensated cirrhosis. (2019) (10)
- Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis. (2021) (10)
- Distinct Roles for Intracellular and Extracellular Lipids in Hepatitis C Virus Infection (2016) (10)
- Assessing the risk of bleeding and clotting in cirrhosis (2016) (10)
- A Case of Retinal Tear Associated with Use of Sorafenib (2014) (10)
- Haemostatic alterations and management of haemostasis in patients with cirrhosis. (2022) (10)
- Gastric Antral Vascular Ectasia Pathogenesis and the Link to the Metabolic Syndrome (2018) (9)
- Clinical and histologic patterns of early graft failure due to recurrnet hepatitis C in four patients after liver transplantation. (1996) (9)
- Propensity for non‐alcoholic fatty liver disease: more evidence for ethnic susceptibility (2009) (9)
- Changes in hemostasis in liver disease. (2017) (9)
- Does external beam radiation therapy improve survival following transarterial chemoembolization for unresectable hepatocellular carcinoma? (2012) (9)
- NASH (Nonalcoholic steatohepatitis): A case of multiorganelle failure. (2014) (8)
- Management of Gastric Varices in the Pediatric Population with Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) Utilizing Sodium Tetradecyl Sulfate Foam Sclerosis with or without Partial Splenic Artery Embolization (2015) (8)
- The fat droplet in hepatocellular ballooning and implications for scoring nonalcoholic steatohepatitis therapeutic response (2016) (8)
- Obesity and Hepatocellular Carcinoma: A Complex Relationship. (2015) (8)
- Imaging and clinical characteristics of focal atrophy of segments 2 and 3 in primary sclerosing cholangitis (2001) (8)
- Management of Stomal Varices with Transvenous Obliteration Utilizing Sodium Tetradecyl Sulfate Foam Sclerosis (2014) (8)
- Perspectives on NASH Histology: Cellular Ballooning. (2017) (8)
- Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial. (2018) (7)
- Direct acting inhibitors of ammoniagenesis: a role in post-TIPS encephalopathy? (2014) (7)
- Endoscopic treatment of gastric varices: Use of band ligation, cyanoacrylate glue and novel therapies (2005) (7)
- Effects of restoring portal flow with anticoagulation and partial splenorenal shunt embolization (2015) (7)
- The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC. (2019) (7)
- Ultrastructural findings in human nonalcoholic steatohepatitis (2011) (7)
- The effects of diet composition on body fat and hepatic steatosis in an animal (Peromyscus californicus) model of the metabolic syndrome. (2011) (7)
- The Clinical Outcome of NAFLD Including Cryptogenic Cirrhosis (2007) (7)
- Thrombocytopenia in Patients with Gastric Varices and the Effect of Balloon-occluded Retrograde Transvenous Obliteration on the Platelet Count (2014) (7)
- Longitudinal changes in liver stiffness by magnetic resonance elastography (MRE), liver fibrosis, and serum markers of fibrosis in a multi-center clinical trial in nonalcoholic steatohepatitis (NASH) (2017) (7)
- Intrahepatic biliary endoscopy in sclerosing cholangitis. (1996) (7)
- Management of disordered hemostasis and coagulation in patients with cirrhosis (2014) (7)
- Cholangioscopy to screen for cholangiocarcinoma in primary sclerosing cholangitis (2001) (7)
- Endoscopy for gastrointestinal bleeding after acute myocardial infarction. (1994) (7)
- Healing gone wrong: convergence of hemostatic pathways and liver fibrosis? (2020) (7)
- 17 DISSOCIATED HISTOLOGICAL AND METABOLIC EFFECTS OF OMEGA-3 (3000 MG/D) VERSUS PLACEBO WITH BOTH EXERCISE AND DIET IN A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL OF NASH (2011) (7)
- Two-year outcomes of balloon-occluded retrograde transvenous obliteration of gastric varices in liver transplant recipients: A multi-institutional study. (2017) (6)
- Severe Prolongation of the INR in Spur Cell Anemia of Cirrhosis: True-True and Related? (2006) (6)
- Nonalcoholic Fatty Liver Disease, Portal Vein Thrombosis and Coagulation: More Questions Than Answers? (2017) (6)
- Lung transplantation for severe antineutrophilic cytoplasmic antibody-associated vasculitis. (2010) (6)
- Non-alcoholic fatty liver disease: Hype or harm? (2016) (6)
- Diagnosis and treatment of the major hepatotropic viruses. (1993) (6)
- Coagulation in Cirrhosis (2018) (6)
- pidemiological modifiers of non-alcoholic fatty liver disease : ocus on high-risk groups he non-alcoholic fatty liver disease ( NAFLD ) study group , dedicated to the memory (2015) (6)
- Gastric myoelectric activity in patients with end-stage liver disease. (1999) (6)
- Coagulation Homeostasis in Liver Disease (2020) (6)
- Thrombosis of the Portal Venous System in Cirrhotic vs. Non-Cirrhotic Patients. (2018) (6)
- Portal vein thrombosis and chronic liver disease progression: The closer you look the more you see (2016) (6)
- Serum LYSYL Oxidase-Like-2 (SLOXL2) Levels Correlate with Disease Severity in Patients with Primary Sclerosing Cholangitis (2016) (5)
- Approach to the management of portal hypertensive gastropathy and gastric antral vascular ectasia (2012) (5)
- Corrigendum to "Management of the critically ill patients with cirrhosis: A multidisciplinary perspective". (2016) (5)
- A Pilot Experience of Endoscopic Submucosal Dissection of Barrett’s Dysplasia Despite Esophageal Varices and Decompensated Cirrhosis (2019) (5)
- Liver Biopsy: The Reports of Its Demise Are Greatly Exaggerated (2016) (5)
- Reversing Advanced Hepatic Fibrosis in NASH: Clearly Possible, but Widely at Hand? (2015) (5)
- 573 The ballooned hepatocyte in NAFLD: Degenerative or adaptive? (2004) (5)
- Editorial: Severe Acute Liver Injury: Cause Connects to Outcome (2017) (5)
- Management of Gastric Varices (2014) (4)
- Transplantation of the Liver, 2nd edition, Ronald W. Busuttil, Goran K. Klintmalm (Eds.). Saunders, Philadelphia, Pennsylvania (2005), 1520 pp., www.elsevier.com, ISBN 0721601189. Web address for ordering: (2006) (4)
- Possible role of Campylobacter pylori in idiopathic hyperammonemia. (1989) (4)
- Transcription Factor EB: A Central Regulator of Both the Autophagosome and Lysosome (2012) (4)
- Pearls and pitfalls in nonalcoholic fatty liver disease: tricky results are common (2021) (4)
- 260 The Use of Thromboelastography, Platelets, and INR in a Clinical Model for Bleeding Risk in Cirrhotic Patients (2009) (4)
- Anticoagulation for portal vein thrombosis in cirrhosis (2016) (4)
- Guidelines for Idiopathic Thrombocytopenic Purpura (1997) (4)
- Hyperthyroidism with interferon-ribavirin therapy for hepatitis C: a case report and proposed treatment algorithm (2000) (4)
- Clinical Cirrhosis Dilemmas: Survey of Practice from the 7th International Coagulation in Liver Disease Conference (2019) (4)
- Abnormal cholesterol metabolism underlies relative adrenal insufficiency in decompensated cirrhosis (2021) (4)
- Abstract No. 87: Bleeding gastric varices obliteration with BRTO (balloon-occluded retrograde transvenous obliteration) utilizing sodium tetradecyl sulfate foam (2010) (4)
- The direct oral anticoagulants in patients with and without liver disease (2017) (4)
- THU-272-A study investigating the effect of extracorporeal cellular therapy with C3A cells on the survival of alcoholic hepatitis designed along the guidelines of the NIAAA (2019) (4)
- The Reply. (2017) (3)
- Nonalcoholic Fatty Liver (NAFL): Overview (2005) (3)
- Its Effect on Pleural Fluid Chemistry (2015) (3)
- Treatment of bleeding gastric varices (2005) (3)
- Abstract No. 76: The effect of balloon-occluded retrograde transvenous obliteration (BRTO) on the model for end stage liver disease (MELD) score (2011) (3)
- Sexual, vertical and household transmission of hepatitis C. (1995) (3)
- Erratum to: Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry (2016) (3)
- A Randomized Controlled Trial of Procedural Techniques for Large Volume Paracentesis. (2017) (3)
- Clinical outcomes of BRTO only versus BRTO and TIPS for the management of gastric variceal bleeding: A multi center USA study (2013) (3)
- Relationship between Baseline Hepatic Disease Severity and the Cardiometabolic and Anti-Inflammatory Effects of Elafibranor in Patients with Non-Alcoholic Steatohepatitis (2016) (2)
- Hypothesis of Peptic Ulcer: A Modern Classification of a Multifactorial Disease (1991) (2)
- Successful retransplantation for recurrent posttransplant hepatitis B virus infection in the primary allograft. (1996) (2)
- Hemostasis in chronic liver disease (2006) (2)
- University of Groningen Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease faculty of the 7th International Coagulation in Liver Disease (2018) (2)
- Evaluation of SOMAscan as a discovery platform to identify noninvasive protein biomarkers for diagnosis and monitoring of NASH (2018) (2)
- Treatment with selonsertib, an inhibitor of apoptosis signal-regulating kinase 1, hepatic phospho-p38 expression and markers of hepatocellular apoptosis and necrosis in patients with nonalcoholic steatohepatitis (2017) (2)
- Nonalcoholic Fatty Liver Disease: Prognosis and Progression of Disease (2016) (2)
- Haemostasis in Liver Disease (2008) (2)
- Hyperthyroidism with interferon-ribavirin therapy for hepatitis C: a case report and proposed treatment algorithm. (2000) (2)
- 19 – The Hemostatic and Hematopoietic System in Liver Disease (2018) (2)
- Impact of modest weight reduction on liver histology, portal pressure, and clinical events in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (2017) (2)
- A single center's experience with acute alcoholic steatohepatitis: Corticoserolds compared to combination ursodeoxycholic acid, vitamin C, and vitamin E (2001) (2)
- Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC. (2022) (2)
- Efficacy and Safety of Troglitazone for Lipodystrophy Syndromes (2001) (2)
- Ectopic varices: Hidden challenges in the vascular anatomy. (2016) (2)
- Coagulation and hemostasis in liver disease: controversies and advances. Preface. (2009) (1)
- The strange and critical intersection of hepatitis C and lipoprotein metabolism: “C‐zing” the oil (2013) (1)
- A Post-Hoc Analysis ofthe Golden505 Trial Demonstrates Histological and Cardiometabolic Efficacy of Elafibranor-120 Mg in Patients with Moderate or Severe Nash That Are Eligible for Pharmacotherapy (2016) (1)
- Hemostasis in chronic liver disease (2006) (1)
- How useful is ε-aminocaproic acid for the treatment of hyperfibrinolysis in patients with cirrhosis? (2006) (1)
- Treating NAFLD: future prospects. (2006) (1)
- Significance of isolated pretransplant hepatitis B anticore antibody. (1997) (1)
- Correlation between the Hepatic Venous Pressure Gradient and Alpha-Smooth Muscle Actin (SMA) Expression in Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (2016) (1)
- Implementing a Treatment Protocol Reduces Inpatient Cost of Hepatic Encephalopathy (2011) (1)
- Recent Advances in the Treatment of NASH. (2006) (1)
- Management of the critically ill patients with cirrhosis: A multidisciplinary perspective (vol 64, pg 717, 2016) (2016) (1)
- A Summary of the 6th International Conference on Coagulation in Liver Disease: Discussion, Debate, Deliberations. (2017) (1)
- The association of circulating microRNAs (miRs) with liver fibrosis stage and the impact of selonsertib treatment in patients with NASH (2018) (1)
- 719 Refinement of a clinicopathological typing system for non-alcoholic fatty liver disease (NAFLD): clinical, biochemical, and pathological features in 98 patients with NAFLD (2003) (1)
- Diagnostic testing for decompensated cirrhosis-striking a better balance in a new era. (2015) (1)
- Post-Treatment Ulceration and Bleeding After Cyanoacrylate Injection of Duodenal Varices (2020) (1)
- 225 PRO-COAGULANT BLOOD PRODUCT USAGE IN LIVER DISEASE PATIENTS (2009) (1)
- Altered lipid metabolism influences course of hepatitis C virus infection and hepatocyte cytokine production (VIR1P.1011) (2014) (1)
- Hepatology highlights. (2016) (1)
- 931 EXPRESSION OF PERILIPIN AND ADIPOPHILIN IN HUMAN NONALCOHOLIC FATTY LIVER DISEASE AND THEIR RELATION TO OXIDATIVE DAMAGE (2008) (1)
- PLPNA3 Status in Nash is Associated with Increased Histological Severity at Baseline but Not with Response to Therapy in the Golden-505 Elafibranor Trial (2016) (1)
- Reversibility of alcohol‐related brain atrophy (2000) (1)
- Hepatology Is exercise an effective treatment for NASH? Knowns and unknowns (2009) (1)
- Risk factors for transmission of hepatitis C in patients with alcoholic liver disease. (1993) (1)
- Success of Direct-Acting, Antiviral-Based Therapy for Chronic Hepatitis C Is Not Affected by Type 2 Diabetes (2020) (1)
- Characterization of Baseline Thrombopoietin Levels in Patients With Chronic Liver Disease: Results From 2 Pooled Clinical Studies in Patients With Thrombocytopenia and Liver Disease (2018) (1)
- Liver invasion of the duodenum due to hepatocellular carcinoma. (2012) (1)
- Patients with Nonalcoholic Steatohepatitis and Advanced Liver Disease Have the Lowest Cardiorespiratory Fitness (2023) (1)
- Hepatic Proton Density Fat Fraction Correlates with Histologic Measures of Steatosis and is Responsive to Change in those Measures in a Multi-Center Nonalcoholic Steatohepatitis Clinical Trial (2017) (1)
- Reply to: "Bleeding Risk and Management in Interventional Procedures in Chronic Liver Disease". (2017) (1)
- S1292 Sorafenib in Combination With Locoregional Therapy for Hepatocellular Carcinoma in Patients on the Liver Transplant Waiting List: One Center's Experience (2010) (1)
- Rbc Lipid Composition Is Favorably Altered in Nash Patients Treated with Omega-3 Fish Oil versus Placebo: 609 (2013) (1)
- Antral mucosal perfusion is not increased in GAVE (2017) (1)
- THE PAST AS PROLOGUE — CIRRHOSIS AS THE EPITOME OF THE HEMORRHAGIC DISEASES ? (2016) (1)
- Therapy of NAFLD: Insulin Sensitizing Agents. (2006) (1)
- Is cryptogenic cirrhosis burned-out nonalcoholic steatohepatitis? (2003) (1)
- Laboratory Predictors of Risk for Developing Hepatocellular Carcinoma in Cirrhosis: 524 (2013) (0)
- On the Farm (2001) (0)
- Bleeding after liver biopsy: Remarkably infrequent but potentially serious and unfortunately unpredictable by extensive clinical laboratory analyses—Take a closer look at the biopsy? (2022) (0)
- Laboratory Predictors of Risk for Developing Hepatocellular Carcinoma in Cirrhosis (2018) (0)
- Author reply to comment on "Bleeding and thrombosis in cirrhotic patients: What really matters?" (2012) (0)
- Sa1467: PROVIDER PERCEPTIONS OF FRESH FROZEN PLASMA TRANSFUSION IN VARICEAL BLEEDING LAG BEHIND CURRENT EVIDENCE AND VARY ACROSS CLINICAL SPECIALTIES (2022) (0)
- ADVANCES IN HEPATOLOGY Management of Cardio-Fundal Gastric Varices (2008) (0)
- Thrombosis of the Portal Venous System in Cirrhotic Patients. (2018) (0)
- Response to Mancuso et al. (2020) (0)
- PS-012-Validation of histologic and non-invasive measures of fibrosis as surrogate end points of disease progression in patients with primary sclerosing cholangitis (2019) (0)
- Use of Newer Anticoagulants in Patients with Cirrhosis (2022) (0)
- of the Mexican Association of Hepatology , the Latin-American Association for Study of the Liver and the Canadian Association for the Study of the Liver Hepatology highlights (2016) (0)
- J-Pouch Ectopic Varices: A Rare Cause of Lower GI Bleed: 1913 (2017) (0)
- BRTO of gastric varices without an indwelling balloon: comparison between conventional BRTO with an indwelling balloon vs. intraprocedural replacement of the balloon with an amplatzer vascular plug (2013) (0)
- YoJyoHenShiKo , a novelChinese herbal , prevents nonalcoholic steatohepatitis in ob / obmice feda high fatormethionine ^ choline-de ¢ cientdiet (2007) (0)
- 1876-P: Impact of Diabetes on Liver Disease Progression in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH) (2019) (0)
- Comprar Coagulation and Hemostasis in Liver Disease: Controversies and Advances, An Issue of Clinics in Liver Disease | Arun J. Sanyal | 9781437704952 | Saunders (2009) (0)
- S2659 SARS-CoV-2-Associated Cholestatic Liver Injury: A Case Series in Critically Ill Patients (2021) (0)
- Mo1894 Sonorheometry, A Novel Coagulation Measurement, and Thromboelastography Show Relative Hypercoaguability in Patients With Decompensated Cirrhosis (2015) (0)
- GUIDELINES FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA. AUTHORS' REPLY (1997) (0)
- Diagnostic laparoscopy of the liver and peritoneum using conscious sedation. (1995) (0)
- Hepatology highlights (2002) (0)
- Primary biliary cirrhosis. (1997) (0)
- Comparison of Long-Term Survival in BRTO (Balloon-Occluded Retrograde Transvenous Obliteration) versus Endoscopic Cyanoacrylate for Management of Bleeding Gastric Varices (2016) (0)
- Serum bile acids are markedly elevated in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH) (2018) (0)
- Acute alcoholic myopathy. (1984) (0)
- Therapeutic and Prophylactic Anticoagulation in Cirrhosis Patients (2020) (0)
- W1774 Cost Effectiveness of Radiofrequency Ablation Versus Transcatheter Arterial Chemoembolization in Patients with Hepatocellular Carcinoma Less Than 4.5 CM in Diameter (2009) (0)
- Unrecognized alpha-1 antitrypsin carriage in liver donors (1996) (0)
- 32. Nonalcoholic Fatty Liver Disease (2011) (0)
- Bleeding and Thrombotic Complications in Patients with Cirrhosis: A State of the Art Appraisal. (2023) (0)
- Gastric Mucosal Blood Flow and the Role of Proton Pump Inhibitors in Gastric Antral Vascular Ectasia (GAVE): 2005 (2013) (0)
- Mo1169 GAVE: Another Manifestation of Metabolic Syndrome? (2015) (0)
- Mo1012 Characteristics of Cirrhotic Patients With Concomitant Portal Vein Thrombosis and Non-Splanchnic Venous Thromboembolism (2014) (0)
- Palmitate breath test : A dynamic marker of fatty acid oxidation in non-alcoholic fatty liver disease (2017) (0)
- Tu1069 Initiating Sofosbuvir Based Therapies for Hepatitis C - Does Insurance Matter? (2015) (0)
- Reply: (2011) (0)
- Persistence of Mixed Cryoglobulinemia Despite Cure of Chronic Hepatitis C With Oral Direct Acting Antiviral Therapy: A Case Series: 1215 (2014) (0)
- 289 Comparison of two different cyanoacrylates: what is the optimal cyanoacrylate for treating gastric varices? (2003) (0)
- The Optimal Transfusion Strategy in Liver Transplantation: The Quest Continues. (2017) (0)
- 906 FIXATION TEMPERATURE ALTERS INTRAMITOCHON-DRIAL CRYSTALS (IMC) IN HUMAN NASH: IMPLICATIONS FOR MITOCHONDRIAL CHANGES IN STEATOHEPATITIS (2008) (0)
- The Effect of Acute Kidney Injury on Coagulation Parameters in Patients with Decompensated Cirrhosis: 784 (2016) (0)
- RECOMBINANT FACTOR VIIA—IS IT SAFE OR EFFECTIVE FOR VARICEAL BLEEDING IN CIRRHOSIS? (2008) (0)
- Coagulation Disorders and Portal Vein Thrombosis in Cirrhosis (2013) (0)
- Changes in liver disease hemostasis (2017) (0)
- Treatment Targets and Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH): A Summary of AALSD Trend Conference in NASH (2020) (0)
- Response to Di Benedetto: “sorafenib before liver transplantation for hepatocellular carcinoma: risk or give up?” (2011) (0)
- Reply to "HbA1c levels as a parameter of glycemic control in patients with liver cirrhosis". (2017) (0)
- Defining NAFLD , NASH , and the Meaning of “ Nonalcoholic ” (2003) (0)
- The Liver and Insulin Resistance: The Important Convergence of Endocrinology and Hepatology (2019) (0)
- 942 A NEW RODENT MODEL REPRODUCES NASH WITH CIRRHOSIS, OVAL CELL PROLIFERATION AND HEPATOCELLULAR CARCINOMA (HCC) (2008) (0)
- Endoscopic Placement of Sengstaken-Blakemore Tube for Bleeding Esophageal Varices: 1608 (2017) (0)
- Whole exome sequencing identifies rare nonsense mutations enriched among patients with advanced fibrosis due to nonalcoholic steatohepatitis (2018) (0)
- Insulin Sensitizing Agents (2006) (0)
- Endoscopy in the Setting of Coagulation Abnormalities in the Patient with Liver Disease (2017) (0)
- Reply to: "Re: Bleeding Risk and Management in Interventional Procedures in Chronic Liver Disease". (2017) (0)
- The Prevalence of Spur Cell Anemia in Hospitalized Cirrhotics and Its Relationship to Coagulation, Hemolysis and HDL Cholesterol: 322 (2006) (0)
- Gastric myoelectrical activity in patients with end stage liver disease (1994) (0)
- Nipple-like projection from a varix: a high-risk marker? (1996) (0)
- Cryptogenic Cirrhosis (2018) (0)
- Radiologic Management of Gastric Varices Clinical Condition: Radiologic Management of Gastric Varices (2013) (0)
- Large Volume Paracentesis: Z-Tract or Coaxial Insertion Technique? Preliminary Data From a Randomized Controlled Trial: 458 (2014) (0)
- The Desialylated Transferrin Ratio Does Not Increase with Clinical-Disease Severity Nor with Presence of Hepatitis-C in Alcoholic Patients (1993) (0)
- Balloon-occluded retrograde transvenous obliteration (BRTO) utilizing 3% sodium tetradecyl sulfate (STS) (3%) foam for the management of gastric variceal bleeding: a multicenter USA study of 100 patients (2013) (0)
- Management of cardio-fundal gastric varices. (2008) (0)
- Methylation signatures in blood show accelerated epigenetic aging in patients with non-alcoholic steatohepatitis compared to healthy controls (2017) (0)
- Treatment of Hepatitis C Virus Infection (2015) (0)
- Plasma Transfusion in Cirrhotic Patients Undergoing Hernia Repair: 498 (2014) (0)
- Treating NAFLD: Future Prospects. (2006) (0)
- The Optimal Transfusion Strategy in Liver Transplantation: The Quest Continues. (2017) (0)
- Reply: (2006) (0)
- P1026 A NEW ECL-BASED ASSAY TO MEASURE SERUM CYTOKERATIN-18 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (2014) (0)
- Natural History of Non-Splanchnic Venous Thromboembolism in Cirrhosis: A Single-Center Review: 424 (2013) (0)
- Hepatic Outflow Syndromes and Splanchnic Venous Thrombosis (2010) (0)
- Autoimmune Liver Diseases, 2nd Edition (1999) (0)
- PNPLA3 Variants Confer an Increased Risk of Advanced Fibrosis Due to Non-Alcoholic Steatohepatitis (2016) (0)
- Novel characterization of the gut microbiome in patients with NASH and longitudinal changes associated with histological improvement (2018) (0)
- Effects of fialuridine on hepatitis B immune globulin pharmacokinetics following orthotopic liver transplant for chronic hepatitis B viral-induced cirrhosis. (1995) (0)
- What Are the Best Diagnostic Modalities for Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis and Associated Fibrosis? A Summary of AALSD Trend Conference in NASH (154/120) (2020) (0)
- 972 MOLECULAR PROFILES IN HUMAN NONALCOHOLIC STEATOHEPATITIS (NASH)-RELATED HEPATOCELLULAR CARCINOMA (HCC) ASSESSED BY WHOLE GENOME BIOARRAY HYBRIDIZATION (2008) (0)
- O anima mea : two voices and continuo (2014) (0)
- Serum fibroblast growth factor 19, 7α-Hydroxy-4-Cholesten-3-one, and bile acids and their associations with clinical characteristics in primary sclerosing cholangitis (2017) (0)
- A Complication of Paracentesis Due to Hyperfibrinolysis: Hemoperitoneum (2013) (0)
- Creation of a transjugular intrahepatic portosystemic shunt with use of a preexisting portal-hepatic vein fistula as an alternative route. (2005) (0)
- DECREASED HEPATITIS C VIRAL RNA AT TREATMENT IS A PREDICTOR OF SUCCESSFUL ANTI-HEPATITIS C TREATMENT AND VIROLOGIC RESPONSE: 2058 (2010) (0)
- Impact of an Institutional Change in Prothrombin Time Methodology on INR and MELD Scores in Liver Transplant Evaluations (2016) (0)
- Undetectable Alanine Aminotransferase during Hospitalization. (2016) (0)
- S2917 Acute Alcoholic Hepatitis With Portal Hypertension Complicated by Tuberculous Peritonitis and Ascites (2022) (0)
- Iconographies supplémentaires de l'article : Two-year outcomes of balloon-occluded retrograde transvenous obliteration of gastric varices in liver transplant recipients: A multi-institutional study (2017) (0)
- 333 POLYUNSATURATED FATTY ACID COMPOSITION IN ERYTHROCYTE LIPID MEMBRANES IN NASH: UNEXPECTED HETEROGENEITY IN THE N6-N3 RATIO (2010) (0)
- Reply: (2009) (0)
- Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis (PSC) (2018) (0)
- THE LIVER AS A FAT STORING ORGAN? ADAPTATION AND MALADAPTATION IN NAFLD. (2004) (0)
- Response to Dr. Azer (2003) (0)
- How useful is epsilon-aminocaproic acid for the treatment of hyperfibrinolysis in patients with cirrhosis? (2006) (0)
- Skin Color and Ethnicity (1995) (0)
- Bone Grafting Complications (2018) (0)
- Reply to "HbA1c Levels as a Parameter of Glycemic Control in Patients with Liver Cirrhosis". (2017) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Stephen Hugh Caldwell?
Stephen Hugh Caldwell is affiliated with the following schools:
